

February 10, 2023 | Issue 258

Editor's note

This note is produced every Friday by the <u>KPMG Center for Healthcare</u> <u>Regulatory Insight</u> and is intended to be short and succinct, no more than 360 words, to provide a digestible bite of healthcare and life sciences news from the past week. Please share this email with colleagues and other interested individuals, and encourage them to <u>subscribe to our mailing list here</u>.

We welcome your feedback. Let us know if KPMG can help. Please <u>reply</u> <u>here to me</u>, **Larry Kocot**, principal and national leader, KPMG Center for Healthcare Regulatory Insight or simply reply to this email with any comments or requests.





Healthcare regulatory news

CMS <u>released initial guidance</u> for implementing Medicare <u>Part B</u> and <u>Part D</u> drug inflation rebates, with manufacturer invoices beginning in 2025... OIG <u>recommended CMS take actions</u> to remedy administrative challenges in administering the Part B inflation rebates.

Department of Justice (DOJ) <u>announced it collected \$1.7B</u> in <u>healthcare-related False Claims Act settlements/judgments</u> in FY2022, down from <u>\$5B+ in FY2021</u>... DOJ's Antitrust Division <u>withdrew three "outdated" policy statements</u> on healthcare antitrust enforcement that were "overly permissive on certain subjects."

GAO <u>recommended CMS improve nursing-home-ownership transparency</u> in its consumer comparison tool.

FDA <u>granted priority review</u> to Sage's rapid-acting depression treatment... FDA <u>expanded approval of a Gilead oncology drug</u> to include the most common type of breast cancer.



Healthcare law and policy news

During his <u>State of the Union address</u>, President Biden, among things, called on Congress to <u>expand the \$35/month insulin price cap</u> to all Americans, make <u>enhanced ACA subsidies permanent</u>, and disrupt fentanyl supply chains.

A <u>district court struck down portions</u> of a surprise billing arbitration rule, including the <u>requirement that arbiters primarily consider the qualifying payment amount</u> (QPA)... A federal district court <u>dismissed a PhRMA lawsuit</u> seeking to <u>block states</u>' plans for drug importation from Canada.

Banner Health will pay \$125M to settle a HIPAA investigation over a cybersecurity breach... Centene will pay California \$215M over allegedly overcharging the state for Medicaid pharmacy services.

CVS is close to acquiring Oak Street Health (\$10.6B)... Abbott will acquire Cardiovascular Systems (\$890M)... Globus Medical will acquire NuVasive (\$3.1B)... Danaher is considering acquiring Catalent... Carlyle Group is considering acquiring Cotiviti (\$15B).

Health Affairs studies found: (1) the proportion of primary care visits for a mental health condition increased from 10.7% in 2006-2007 to 15.9% in 2016 and 2018; and, (2) Medicare Advantage enrollment grew 337% (22.2M) from 2006-2022, while traditional Medicare enrollment dropped 2.9% (1M)... A JAMA study found, among 2020 top-selling prescription drugs, manufacturers spent a higher proportion of direct-to-consumer promotional spending on "lower added benefit" products.

A Patient Rights Advocate report found <u>just 24.5% of 2,000 hospitals studied</u> were fully compliant with price transparency requirements; 5.8% were fully noncompliant.

Senate Judiciary Committee <u>advanced five bipartisan bills</u> to <u>boost generic and</u> biosimilar competition.

Healthcare added 58,000 jobs in January.

-



Special Section: COVID-19 and Other Respiratory Illnesses News

HHS released a COVID-19 public health emergency (PHE) transition roadmap and informed governors that the PHE would expire on May 11.

CMS stated that uninsured individuals enrolled in the optional Medicaid group offered by some states for COVID-19 vaccines, testing, and treatment will lose coverage once the PHE ends on May 11, unless the state decides to pick up the costs... CMS also clarified that Medicare will not cover the cost of COVID-19 at-home tests after the PHE.

CDC $\underline{added\ COVID-19\ vaccinations}$ to immunization schedules for \underline{adults} and $\underline{children}$.

A <u>Premier analysis found that 69% of providers are still using</u> pandemic-related waivers and other flexibilities that will expire at the end of the PHE; 80% of organizations have a plan to unwind the waivers.

FDA encouraged individuals to report results of their at-home COVID-19 tests on an anonymous reporting site set up by NIH, MakeMyTestCount.org.

A <u>JAMA</u> study found, due to the pandemic, breast and lung cancer screenings were 14.6% and 30.5% below expectations, respectively, in January 2021.

A KFF survey found 38% of respondents were in households affected by COVID-19, the flu, or RSV over the past month or so; 46% of respondents were more likely to take at least one protective measure to prevent infection from one of the three viruses.





Questions or comments, please send to <u>us-hclspractice@kpmg.com</u>.

kpmg.com/socialmedia











Privacy | Legal

You have received this message from KPMG LLP. If you wish to unsubscribe from Around the world of U.S. healthcare in 360 words or less, please $\underline{\text{click here}}$. If you wish to unsubscribe from all KPMG communications, please $\underline{\text{click here}}$.

KPMG LLP, 3 Chestnut Ridge Road, Montvale, NJ 07645

© 2023 KPMG LLP, a Delaware limited liability partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved. NDP295619-1E

The KPMG name and logo are trademarks used under license by the independent member firms of the KPMG global organization.